On April 16, 2014, Zalicus Inc. (ZLCS) announced that it has entered into a definitive agreement with Epirus Biopharmaceuticals, a privately-held biopharma company focused on the global development and commercialization of biosimilar monoclonal antibodies. The merger will create a Nasdaq-listed, publicly traded company focused on building a global biosimilar enterprise. We discuss Epirus, its pipeline, and how Zalicus fits into the new organization below. However, first let's discuss the terms of the agreement.
The percentage of the combined company that Zalicus stockholders will own as of the closing of the merger is subject to adjustment based on the level of Zalicus' net cash at the closing date. The ownership of current Zalicus stockholders will be:
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|